Bioanalytical Systems, Inc., to Report First Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, Febru...
January 26 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”,
“We”, “Our” or “Inotiv”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, today announced that the Company will issue its financial
results press release for the fiscal 2021 first quarter ended
December 31, 2020, on Tuesday, February 9, 2021, after the close of
the stock market, and host a conference call the same day at 4:30
p.m. Eastern Time to discuss the results.
Interested parties may participate in the call
by dialing:
- (877) 407-9753 (Domestic)
- (201) 493-6739 (International)
The live conference call webcast will be
accessible in the Investors section of the Company’s website, and
directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/bas2/mediaframe/43273/indexl.html
For those who cannot listen to the live
broadcast, an online replay will be available in the Investors
section of Inotiv’s web site at:
https://www.inotivco.com/investors/investor-information/.
About the Company
Bioanalytical Systems, Inc., doing business as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more information
about the Company.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the
successful closing, integration and business and financial impact
thereof, the impact of the COVID-19 pandemic on the economy,
demand for our services and products and our operations, including
the measures taken by governmental authorities to address the
pandemic, which may precipitate or exacerbate other risks and/or
uncertainties and various other market and operating risks,
including those detailed in the Company's filings with the U.S.
Securities and Exchange Commission.
Company Contact |
Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Kalle Ahl, CFA |
(765) 497-8381 |
(212) 836-9614 |
btaylor@inotivco.com |
kahl@equityny.com |
|
|
|
Devin Sullivan |
|
(212) 836-9608 |
|
dsullivan@equityny.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024